Cytokinetics Incorporated
Business Description
Cytokinetics Incorporated is a biopharmaceutical company that is dedicated to developing small molecule drugs that can be used to treat a variety of diseases. The company was founded in 1997 and is headquartered in South San Francisco, California. Since its inception, Cytokinetics has focused on developing drugs that can enhance the function of the muscles in the body, with an emphasis on skeletal and cardiac muscle.
Cytokinetics has developed a number of investigational drugs that are intended to improve the function of the heart and skeletal muscles. The company has developed a drug called omecamtiv mecarbil that is intended to improve the contractility of cardiac muscle. This drug is currently being tested in several clinical trials for the treatment of heart failure. Cytokinetics has also developed a drug called reldesemtiv that is intended to improve skeletal muscle function in people with amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
In addition to its investigational drugs, Cytokinetics has developed a number of partnerships with other companies and academic institutions. The company has partnered with companies like Amgen and Astellas to advance and develop its investigational drugs. It has also worked with academic institutions like the University of California, San Francisco and the University of Michigan to further explore the science behind its drug development.
Cytokinetics has received numerous grants and awards for its drug development efforts. In 2013, the company received a grant from the National Institute of Neurological Disorders and Stroke to support the development of reldesemtiv for the treatment of ALS. The company has also been recognized by the California Institute for Regenerative Medicine for its work in developing cell therapy approaches for heart disease.
Overall, Cytokinetics has established itself as a leader in the development of drugs that can improve muscle function in a variety of diseases. Its investigational drugs have the potential to improve patient outcomes and benefit the field of medicine as a whole.
|